Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With
Publication/Presentation Date
10-1-2022
Abstract
PURPOSE: The TAPUR Study is a pragmatic phase II basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from two cohorts of patients with colorectal cancer (CRC) with either
METHODS: Eligible patients with measurable CRC were selected for treatment with P + T according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary study end point of disease control (DC; objective response [OR] or stable disease of at least 16 weeks duration [SD16+]). Secondary end points include safety, response duration, progression-free survival (PFS), and overall survival (OS).
RESULTS: Thirty-eight patients with CRC with
CONCLUSION: Although P + T treatment does not appear to have antitumor activity in CRC with
Volume
6
First Page
2200306
Last Page
2200306
ISSN
2473-4284
Published In/Presented At
Gupta, R., Meric-Bernstam, F., Rothe, M., Garrett-Mayer, E., Mangat, P. K., D'Andre, S., Ahn, E. R., O'Lone, R., Halabi, S., Grantham, G. N., & Schilsky, R. L. (2022). Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO precision oncology, 6, e2200306. https://doi.org/10.1200/PO.22.00306
Disciplines
Medicine and Health Sciences
PubMedID
36315917
Department(s)
Hematology-Medical Oncology Division, Department of Medicine
Document Type
Article